- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03327857
Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Simona Reed, PhD
- Phone Number: +1 714 215 0224
- Email: simona.reed@altrubio.com
Study Contact Backup
- Name: Iming Cho, PhD
- Phone Number: 412 +886 2 2627 2707
- Email: iming.cho@altrubio.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
Los Angeles, California, United States, 90095
- David Geffen School of Medicine at UCLA
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami - Sylvester Comprehensive Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- The University of Kansas Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Seidman Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine-Houston Methodist & Texas Children's Hospital
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (must meet all of the following criteria):
Patients must have clinical aGVHD and pathologic findings consistent with the diagnosis by biopsy of at least 1 involved site, and
- progressed after 3 days of treatment with methylprednisolone (MP) 2 mg/kg/day equivalent, or
- did not improve after 7 days of treatment with MP 2 mg/kg/day equivalent, or
- progressed to involve a new organ after treatment with MP 1 mg/kg/day equivalent for skin and upper gastrointestinal (GI) GVHD, or
- recurred during or after a steroid taper
- For single dose phase: Patients must have erythematous manifestations of cutaneous aGVHD. Characteristics of the rash must indicate active inflammation (red coloration) as distinct from resolving inflammation (brown coloration).
- For single dose phase: Providers and patients must be willing to defer new systemic or cutaneous topical treatment of aGVHD for at least 36 hr after administration of Neihulizumab.
- Patient must give informed consent and sign an approved consent form prior to any study procedures.
- Females of childbearing potential must have a negative pregnancy test result before enrollment. Males and females of childbearing potential must agree to use a highly effective method of birth control during the study for at least 30 days after enrollment in the study.
Exclusion Criteria (may not meet any of the following criteria):
- For single dose phase: Prior administration of anti-lymphocyte globulin or anti- thymocyte globulin for treatment of aGVHD.
- For multiple dose phase: Has received any systemic treatment in addition to corticosteroids for aGVHD.
- Stage 4 lower GI GVHD, defined by the presence of ileus, severe abdominal pain, or overt GI bleeding.
- Uncontrolled infections not responding to antimicrobial therapy or requiring intensive critical care or vasopressors.
- Evidence of end-organ cytomegalovirus (CMV) or adenovirus infection.
- Known to have adenovirus, or Epstein Barr virus (EBV) viremia from screening according to institutional standard practice. Patients receiving appropriate antiviral treatment for CMV, HHV6 or hepatitis viremia are eligible on a case-by-case basis.
- HIV infection or a known HIV-related malignancy.
- Tuberculosis, history of tuberculosis or a known positive Quantiferon test for tuberculosis.
- Unplanned donor lymphocyte infusion (DLI) for residual or relapsed malignancy or mixed chimerism. DLI as part of the planned HCT protocol is allowed.
- Known relapsed or progressive malignancy after transplant, posttransplant lymphoproliferative disease or any secondary malignancy diagnosed after HCT.
- Absolute neutrophil count (ANC) <1000/mm3.
- Total serum bilirubin concentration >3.0 mg/dL UNLESS attributed to GVHD.
- Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault equation.
- Sodium (Na) concentration < 130 mmol/L.
- Karnofsky Performance Status (KPS) or Lansky Performance Status < 20%.
- Intensive care unit (ICU) care, life expectancy of less than 28 days, ongoing or unresolved hepatic sinusoidal obstruction syndrome, unstable hemodynamics, or evidence of current or previous clinically significant disease, medical condition or finding (including vital signs and ECG) that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.
- History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients.
- Pregnancy or nursing.
- Less than 12 years of age.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neihulizumab (ALTB-168)
Intravenous doses of Neihulizumab (ALTB-168)
|
Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria. Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of Neihulizumab - AUC
Time Frame: Up to Day 56
|
Including AUC0-t, AUC0-tz, AUC 0-inf
|
Up to Day 56
|
Pharmacokinetics of Neihulizumab - Cmax
Time Frame: Up to Day 56
|
Maximum plasma concentration
|
Up to Day 56
|
Pharmacokinetics of Neihulizumab - tmax
Time Frame: Up to Day 56
|
Time to reach Cmax
|
Up to Day 56
|
Pharmacokinetics of Neihulizumab - Lambda-z
Time Frame: Up to Day 56
|
Terminal phase elimination rate constant
|
Up to Day 56
|
Pharmacokinetics of Neihulizumab - t1/2
Time Frame: Up to Day 56
|
Half life
|
Up to Day 56
|
Pharmacokinetics of Neihulizumab - MRT
Time Frame: Up to Day 56
|
Mean Residence Time
|
Up to Day 56
|
Pharmacokinetics of Neihulizumab - Vz and Vss
Time Frame: Up to Day 56
|
Volume of distribution and volume of distribution at steady state
|
Up to Day 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: Up to Day 180
|
AEs graded according to CTCAE v4.03
|
Up to Day 180
|
To measure the Receptor Occupancy (RO)
Time Frame: Up to Day 56
|
Receptor occupancy will be monitored using a flow cytometry based method
|
Up to Day 56
|
To measure regenerating islet-derived 3-alpha (REG3α) and suppression of tumorigenicity 2 (ST2) as Pharmacodynamics (PD) biomarkers.
Time Frame: Up to Day 56
|
Receptor occupancy will be monitored using a flow cytometry based method
|
Up to Day 56
|
Complete Response (CR)
Time Frame: Day 28
|
To assess the rate of complete response (CR) at Day 28 in patients treated with Neihulizumab
|
Day 28
|
Overall Response Rate (ORR)
Time Frame: Day 28
|
To assess the Overall Response Rate (ORR) at Day 28: CR+PR
|
Day 28
|
Duration of Response
Time Frame: Up to Day 180
|
For subjects with CR at Day 28, duration of response will be assessed according to the time interval from Day 28 to the first occurrence of (1) resumption of Neihulizumab administration or initiation of new systemic treatment for aGvHD or (for patients who have tapered steroids) an increase in corticosteroids to methylprednisolone 2 mg/kg (+/-10%) equivalent or more, or (2) death.
|
Up to Day 180
|
Non Relapse Mortality (NRM)
Time Frame: Day 180
|
Patients will be followed-up for survival for 6 months after the first Neihulizumab treatment
|
Day 180
|
Immunogenicity
Time Frame: Up to Day 56
|
Immunogenicity will be monitored by anti-drug antibody (ADA) ELISA
|
Up to Day 56
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Shih-Yao Lin, MD, PhD, AltruBio, Inc. (formerly AbGenomics International)
- Principal Investigator: Paul Martin, MD, Fred Hutchinson Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017.002.01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Steroid-refractory Acute Graft-versus-Host Disease
-
medac GmbHRecruitingSteroid-refractory Acute Graft-versus-host DiseaseGermany, Spain, France, Poland
-
XenikosNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsTerminatedSteroid-Refractory Acute Graft Versus Host DiseaseUnited States
-
XenikosNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsTerminatedSteroid-Refractory Acute Graft Versus Host DiseaseUnited States, Belgium, Croatia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
medac GmbHRecruitingSteroid-refractory Acute Graft-versus-host DiseaseSpain, Germany, France, Poland, Sweden
-
University of LiegeTerminatedChronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host DiseaseBelgium
-
Nanfang Hospital of Southern Medical UniversityUnknownSteroid-refractory Gastrointestinal Acute Graft Versus Host DiseaseChina
-
Hannah ChoeNational Cancer Institute (NCI); PlexxikonCompletedAcute Graft Versus Host Disease | Steroid Refractory Graft Versus Host DiseaseUnited States
-
Anhui Provincial HospitalRecruitingSteroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)China
-
MaaT PharmaAvailableAcute Graft Versus Host Disease in Intestine | Steroid Refractory GVHDFrance
-
MaaT PharmaRecruitingAcute Graft Versus Host Disease in Intestine | Steroid Refractory GVHDSpain, France, Germany, Austria, Belgium, Italy
Clinical Trials on Neihulizumab (ALTB-168)
-
AltruBio Inc.TerminatedUlcerative ColitisUnited States, Puerto Rico
-
Sameem M. Abedin, MDRecruitingGraft-versus-host DiseaseUnited States
-
Institute for Neurodegenerative DisordersTerminatedAlzheimer's DiseaseUnited States
-
Guangzhou Lupeng Pharmaceutical Company LTD.Recruiting
-
Cerebos Pacific LimitedUnknown
-
Guangzhou Lupeng Pharmaceutical Company LTD.Completed
-
Guangzhou Lupeng Pharmaceutical Company LTD.Completed
-
AbGenomics B.V Taiwan BranchTerminatedAcute Graft Versus Host DiseaseUnited States
-
Newave Pharmaceutical IncRecruitingFollicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Hairy Cell Leukemia | CLL/SLLUnited States